###### Strengths and limitations of this study

-   This is the first study to investigate 2002--2011 trends in prescribing patterns of statins among new statin users in Taiwan.
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-   Data were retrieved from Taiwan's National Health Insurance Research Database with nearly 99% of the Taiwanese population (around 23 million residents) enrolled and 97% of hospitals and clinics throughout the country.
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-   While patients with history of cardiovascular disease were more likely to be prescribed higher intensity statins compared with those without, this difference was not found comparing those with and without diabetes. Appropriateness of statin use among diabetes needs further investigation.

Introduction {#s1}
============

Coronary heart disease accounts for approximately one-third of global deaths in recent years.[@R1] Similarly, cardiovascular diseases (CVD) are leading causes of death in Taiwan.[@R2] Low-density lipoprotein cholesterol (LDL-C) has been identified as one of the major modifiable risk factors of CVD.[@R3] Fundamental lifestyle changes and several medications have been recommended to control blood cholesterol. Among all medicines, 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, or statins, are a major drug class given their efficacy in reducing LDL-C.[@R7] On average, administration of statins helps to lower LDL-C by 20% to 60%.[@R6] In addition to lowering cholesterol, statins are shown to decrease risk of coronary events by 18%, myocardial infarction by 24% and heart failure by 35%.[@R13]

Statins are recommended by major clinical guidelines as the drug of choice for reduction of blood lipids to prevent CVD globally.[@R7] In the USA, the 2013 'American College of Cardiology/American Heart Association (ACC/AHA)' Guideline[@R7] recommends that patients with CVD history or with CVD risk factors, such as high LDL-C and diabetes, receive moderate-to-high-intensity statins.[@R7] The European Society of Cardiology (ESC) and UK's National Institute for Health and Care Excellence guidelines suggest prescribing statins with the highest recommended dose in order to reach target cholesterol level.[@R8] In Taiwan, prescribing of statins generally follows drug coverage requirements under the National Health Insurance (NHI), which recommends the use of statins in patients with CVD risk factors or with high cholesterol level.[@R14] It is reasonable for patients to be prescribed with a statin plus another lipid-lowering agent if triglyceride level is also high.

Statins have been the most commonly prescribed drugs in the world in recent decades; their global market sales reached around \$28.5 billion in 2014.[@R15] Previous studies from the USA and Europe showed substantial increases in statin users, prescription rates and prescribed daily doses of statins over time.[@R17] Likewise in Taiwan statin users grew from 190 000 in 2000 to nearly 600 000 in 2004, and drug expenditures and prescription doses escalated over 200% and 400%, respectively.[@R20] Based on the updated clinical guidelines and related evidence, use of the more intense statin therapy for secondary prevention and initiation of statins for primary prevention among patients who are at a higher risk of CVD has increased.[@R7]

While statins have been the mainstay of cholesterol control and heart attack and stroke prevention for the past 20 years, the treatment paradigm may change with the availability of new drugs that target an enzyme called PCSK9 (PCSK9 inhibitors) in 2015.[@R23] However, little is known about recent statin use in Taiwan.[@R24] The aims of this study were to examine the prescribing patterns of statins over the last decade and to investigate the association between patients' medical history and drug selection of statin. Our study results can be used to improve rational use of statins in light of clinical recommendations. At present, PCSK9 inhibitors are not yet reimbursed by Taiwan's National Health Insurance (NHI). Our findings also provide baseline trends that can be used to examine how new PCSK9 inhibitors, once become available under the NHI, impact the market of cholesterol medications.

Methods {#s2}
=======

This study used claims data from the 2010 Longitudinal Health Insurance Database (LHID2010) derived from Taiwan's National Health Insurance Research Database (NHIRD), which compiles data of over 99% of people (around 23 million residents) in Taiwan.[@R25] LHID2010 contains all the original claims data of 1 million beneficiaries randomly sampled in year 2010 from the NHIRD. LHID2010 data are overall representative of all beneficiaries as no significant differences were found in the distributions of age, gender and average premium rate between individuals in the LHID2010 and the original NHIRD data sets.[@R26] The data set provides information on demographic characteristics, diseases diagnosis, treatment and related medical expenditures, and orders of ambulatory and inpatient care.

New statin users in each year during 2002--2011 were included and formed the study population of each year. New statin users were defined as those who had not taken any statin in the previous years prior to the index date. The index date of every patient in each study year was defined as the date of the first statin prescription in the year. For patients in every study year, only the first prescription that contained any statins was examined in this study. We used the Anatomical Therapeutic Chemical (ATC) codes[@R27] to identify patients who were prescribed any statins, including atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin. Monotherapy was defined as only one statin prescription on the index date, while combination therapy was defined by prescriptions for a statin plus other lipid-lowering drugs (such as fibrates) on the index date.

The main measure was yearly prescription rate of each statin among new statin users. Yearly prescription rate of a specific statin agent was calculated by the number of patients prescribed with the specific statin agent divided by the total number of new statin users in the year. We also calculated the yearly prescription rates of monotherapy/combined statin therapy and of different levels of intensity.

Statins were grouped into three levels of intensity according to their ability to lower LDL-C based on the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol[@R7] and Rosenson *et al* [@R28]: (1) high-intensity statins: atorvastatin ≧40 mg/day, rosuvastatin ≧20 mg/day and simvastatin ≧80 mg/day; (2) moderate-intensity statins: 10 mg/day ≦ atorvastatin \<40 mg/day, 5 mg/day ≦ rosuvastatin \<20 mg/day, 20 mg/day ≦ simvastatin \<80 mg/day, pravastatin ≧ 40 mg/day, lovastatin ≧40 mg/day and fluvastatin ≧80 mg/day; and (3) low-intensity statins: atorvastatin \<10 mg/day, rosuvastatin \<5 mg/day, simvastatin \<20 mg/day, pravastatin \<40 mg/day, lovastatin \<40 mg/day and fluvastatin \<80 mg/day. Daily dose can be calculated from the information of what statin has been prescribed, its dosage form, frequency and number of pills within a certain period.

All new statin users were also classified based on whether they have disease histories of interest (including coronary events, cerebrovascular events, myopathy, liver injury and diabetes) or not. Disease histories were identified by the International Classification of Diseases, 9th edition diagnosis codes for major coronary artery disease (410, 411), major cerebrovascular (430, 431, 433--436), diabetes (250),[@R29] myopathy (792.1, 359.4, 359.8, 359.9) and liver injury (155.0, 155.1, 155.2, 197.7, 230.8, 570, 571.1, 572.2, 572.4, 572.8, 573.3, 573.8, 573.9, 574.0, 574.1, 574.9, 646.7).[@R30] The first three diagnoses relate to use of statin for CVD prevention and the latter two diagnoses related to the potential adverse effects of statins. We anticipate a higher percentage use of higher intensity statins among patients with CVD or diabetes. Myopathy[@R31] and liver toxicity[@R32] (increasing the enzymes aspartate transaminase and alanine transaminase) are two of the main dose-dependent side effects associated with statin use.[@R34] Therefore, it was anticipated that a higher percentage of patients with a history of these diseases would use low-intensity statins. Individuals were defined as having a history of the following diseases if they have a diagnosis within certain years prior to the given year: coronary event (3 years), cerebrovascular event (5 years), diabetes (1 year), myopathy (3 years) and liver injury (3 years).[@R30]

This study applied descriptive statistics to report the prescription rates of each statin and used χ^2^ test to investigate the associations between patients' disease history and statin drug selection. All analyses were carried out with SAS V.9.3 software and Excel 2013.

Results {#s3}
=======

In 2002, 10 299 (\~1.4% of adults aged 18 and over) statin users were identified among the 1 million cohort from LHID2010 dataset ([table 1](#T1){ref-type="table"}). Among statin users, more than half (n=5956; 57.8%) were new users. Statins users grew from 10 299 (\~1.4% of adults) in 2002 to 50 687 (\~6.3% of adults) in 2011, while the proportion of new statin users declined from 57.8% to 35.0%. More women used statins than men (52.3% vs 47.7% in 2011). The average age of new statin users remained steady (58--60 years old) during the study period. Three quarters of new statin users were diagnosed with dyslipidemia. Hypertension accounted for the highest proportion of comorbidities (60.9% in 2011), followed by diabetes (35.3% in 2011); their rates remained steady during the study period. On the contrary, the proportions of other comorbidities, including ischaemic heart disease and chronic liver diseases, slightly declined over time.

###### 

Characteristics of new statin users over time

  Year                               **2002**             **2003**             **2004**             **2005**             **2006**             **2007**             **2008**             **2009**             **2010**             **2011**   
  ---------------------------------- ---------- --------- ---------- --------- ---------- --------- ---------- --------- ---------- --------- ---------- --------- ---------- --------- ---------- --------- ---------- --------- ---------- ---------
  Number of new statin users         5956       57.8%     9056       57.6%     10 924     52.4%     10 253     45.9%     12 178     47.0%     13 535     44.4%     15 233     42.7%     16 499     40.3%     17 509     37.8%     17 755     35.0%
  All statin users                   10 299     100.0%    15 724     100.0%    20 848     100.0%    22 317     100.0%    25 924     100.0%    30 491     100.0%    35 674     100.0%    40 989     100.0%    46 323     100.0%    50 687     100.0%
  **Sex:**                                                                                                                                                                                                                                   
    F                                3232       54.3%     4925       54.4%     5913       54.1%     5523       53.9%     6391       52.5%     7180       53.0%     8043       52.8%     8519       51.6%     9185       52.5%     9278       52.3%
   M                                 2724       45.7%     4131       45.6%     5011       45.9%     4730       46.1%     5787       47.5%     6355       47.0%     7190       47.2%     7980       48.4%     8324       47.5%     8477       47.7%
   **Age:** mean (SD)                58.41      (11.84)   58.22      (12.19)   57.98      (12.40)   58.44      (12.45)   59.01      (12.51)   59.13      (12.45)   59.35      (12.59)   59.28      (12.68)   59.77      (12.73)   59.76      (12.70)
  **Indication and comorbidities**                                                                                                                                                                                                           
   Dyslipidemia (indication)         4457       74.8%     6815       75.3%     8357       76.5%     7844       76.5%     9352       76.8%     10 281     76.0%     11 594     76.1%     12 655     76.7%     13 431     76.7%     13 723     77.3%
   Hypertension                      3564       59.8%     5214       57.6%     6192       56.7%     6005       58.6%     7290       59.9%     8031       59.3%     9122       59.9%     9859       59.8%     10 726     61.3%     10 816     60.9%
   Diabetes                          2092       35.1%     3168       35.0%     3632       33.2%     3639       35.5%     4336       35.6%     4897       36.2%     5378       35.3%     6011       36.4%     6412       36.6%     6262       35.3%
   IHD                               1561       26.2%     2266       25.0%     2530       23.2%     2431       23.7%     2851       23.4%     3078       22.7%     3357       22.0%     3513       21.3%     3680       21.0%     3536       19.9%
   Heart failure                     217        3.6%      326        3.6%      367        3.4%      384        3.7%      462        3.8%      486        3.6%      562        3.7%      590        3.6%      644        3.7%      637        3.6%
   Afib                              36         0.6%      69         0.8%      74         0.7%      91         0.9%      120        1.0%      141        1.0%      173        1.1%      220        1.3%      188        1.1%      239        1.3%
   CeVD                              749        12.6%     1121       12.4%     1245       11.4%     1216       11.9%     1472       12.1%     1626       12.0%     1822       12.0%     1879       11.4%     2090       11.9%     2019       11.4%
   PVD                               228        3.8%      344        3.8%      414        3.8%      377        3.7%      478        3.9%      455        3.4%      566        3.7%      591        3.6%      671        3.8%      654        3.7%
   CKD                               384        6.4%      497        5.5%      540        4.9%      521        5.1%      608        5.0%      689        5.1%      777        5.1%      839        5.1%      878        5.0%      1027       5.8%
   CLD                               1301       21.8%     1867       20.6%     2107       19.3%     1984       19.4%     2142       17.6%     2288       16.9%     2409       15.8%     2585       15.7%     2758       15.8%     2689       15.1%
   COPD                              576        9.7%      817        9.0%      977        8.9%      871        8.5%      919        7.5%      996        7.4%      1017       6.7%      1106       6.7%      1141       6.5%      1065       6.0%
   Dementia                          49         0.8%      72         0.8%      82         0.8%      83         0.8%      110        0.9%      158        1.2%      199        1.3%      226        1.4%      315        1.8%      298        1.7%
   Malignancy                        165        2.8%      255        2.8%      325        3.0%      305        3.0%      397        3.3%      479        3.5%      546        3.6%      655        4.0%      702        4.0%      752        4.2%

Unit: number of patient.

Afib, atrial fibrillation; CeVD, cerebrovascular diseases; CKD, chronic kidney diseases; CLD, chronic liver diseases; COPD, chronic obstructive pulmonary disease; IHD, ischaemic heart disease; PVD, peripheral vascular diseases.

[Table 2](#T2){ref-type="table"} presents the statin choices among new statin users. Atorvastatin was the most commonly prescribed statin among new statin users throughout the study (33.8% in 2002 and 35.8% in 2011). Lovastatin had the second highest prescription rates from 24.7% in 2002 to 24.2% in 2006, but it declined after 2007 to 5.8% in 2011. On the other hand, simvastatin became the second commonly used statin since 2007 (21.7%), and its prescription rate peaked in 2009 (27.1%). Rosuvastatin entered the market in 2005, and its prescription rate rapidly increased to 19.5% in 2011. Prescription rates of other statins remained relatively low. [Figure 1](#F1){ref-type="fig"} shows the prescribing trends of statins over time.

![Prescribing rates of statins among new statin users from 2002 to 2011. All values were calculated in patient number. Yearly prescription rate = number of patients prescribed with the specific statin agent / total number of new statin users in the year.](bmjopen-2016-014150f01){#F1}

###### 

Prescription rates of statins among new statin users

  Year                                        **2002**               **2003**               **2004**                 **2005**                 **2006**                 **2007**                 **2008**                 **2009**                 **2010**                 **2011**     
  ------------------------------------------- ---------- ----------- ---------- ----------- ------------ ----------- ------------ ----------- ------------ ----------- ------------ ----------- ------------ ----------- ------------ ----------- ------------ ----------- ------------ -----------
  Yearly cohort size                          5956                   9056                   10 924                   10 253                   12 178                   13 535                   15 233                   16 499                   17 509                   17 755       
  **Overall**                                                                                                                                                                                                                                                                           
   Atorvastatin                               2014       33.8%       3320       36.7%       3926         35.9%       3610         35.2%       3883         31.9%       4101         30.3%       4322         28.4%       4912         29.8%       5841         33.4%       6357         35.8%
   Fluvastatin                                710        11.9%       855        9.4%        1063         9.7%        1159         11.3%       1109         9.1%        1214         9.0%        1284         8.4%        1193         7.2%        1186         6.8%        1063         6.0%
   Lovastatin                                 1473       24.7%       2829       31.2%       3595         32.9%       3112         30.4%       2951         24.2%       2298         17.0%       1965         12.9%       1724         10.4%       1242         7.1%        1025         5.8%
   Pravastatin                                654        11.0%       791        8.7%        813          7.4%        687          6.7%        766          6.3%        776          5.7%        1005         6.6%        1122         6.8%        1438         8.2%        1676         9.4%
   Rosuvastatin                               NA                     NA                     NA                       348          3.4%        1690         13.9%       2216         16.4%       2739         18.0%       3082         18.7%       3396         19.4%       3464         19.5%
   Simvastatin                                1106       18.6%       1262       13.9%       1529         14.0%       1339         13.1%       1786         14.7%       2940         21.7%       3920         25.7%       4478         27.1%       4412         25.2%       4190         23.6%
  **Monotherapy**                             **5872**   **98.6%**   **8908**   **98.4%**   **10 765**   **98.5%**   **10 137**   **98.9%**   **12 011**   **98.6%**   **13 055**   **96.5%**   **14 590**   **95.8%**   **15 594**   **94.5%**   **16 540**   **94.5%**   **16 695**   **94.0%**
   Atorvastatin                               1984       33.8%       3276       36.8%       3861         35.9%       3572         35.2%       3829         31.9%       4042         31.0%       4266         29.2%       4826         30.9%       5727         34.6%       6224         37.3%
   Fluvastatin                                701        11.9%       840        9.4%        1045         9.7%        1145         11.3%       1093         9.1%        1197         9.2%        1268         8.7%        1163         7.5%        1168         7.1%        1034         6.2%
   Lovastatin                                 1457       24.8%       2777       31.2%       3556         33.0%       3089         30.5%       2915         24.3%       2264         17.3%       1948         13.4%       1691         10.8%       1224         7.4%        1006         6.0%
   Pravastatin                                637        10.8%       772        8.7%        799          7.4%        671          6.6%        745          6.2%        758          5.8%        992          6.8%        1108         7.1%        1400         8.5%        1628         9.8%
   Rosuvastatin                               NA         NA          NA         NA          NA           NA          343          3.4%        1665         13.9%       2164         16.6%       2680         18.4%       3016         19.3%       3316         20.0%       3386         20.3%
   Simvastatin                                1093       18.6%       1243       14.0%       1504         14.0%       1317         13.0%       1764         14.7%       2630         20.1%       3436         23.6%       3790         24.3%       3705         22.4%       3417         20.5%
  **Combination**                             **84**     **1.4%**    **148**    **1.6%**    **159**      **1.5%**    **116**      **1.1%**    **167**      **1.4%**    **480**      **3.5%**    **643**      **4.2%**    **905**      **5.5%**    **969**      **5.5%**    **1060**     **6.0%**
   Statin + fibrate                           70         83.3%       94         63.5%       132          83.0%       95           81.9%       124          74.3%       160          33.3%       161          25.0%       210          23.2%       226          23.3%       249          23.5%
   Statin + ezetimibe                         0          0.0%        0          0.0%        0            0.0%        0            0.0%        7            4.2%        280          58.3%       454          70.6%       638          70.5%       652          67.3%       702          66.2%
   Statin + others                            14         16.7%       58         39.2%       28           17.6%       22           19.0%       36           21.6%       47           9.8%        30           4.7%        60           6.6%        95           9.8%        114          10.8%
  **Different intensity of statin therapy**                                                                                                                                                                                                                                             
   Low                                        3039       51.0%       4490       49.6%       5112         46.8%       4518         44.1%       4477         36.8%       4100         30.3%       4065         26.7%       4602         27.9%       4954         28.3%       4852         27.3%
   Moderate                                   2918       49.0%       4564       50.4%       5785         53.0%       5688         55.5%       7591         62.3%       9261         68.4%       10 903       71.6%       11 634       70.5%       12 200       69.7%       12 599       71.0%
   High                                       1          0.0%        6          0.1%        32           0.3%        49           0.5%        118          1.0%        187          1.4%        272          1.8%        279          1.7%        365          2.1%        333          1.9%

Statins were grouped into three levels of intensity according to its ability of lowering LDL-C based on the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol[@R7] and Rosenson *et al* [@R28]: (1) high-intensity statins: atorvastatin ≧40 mg/day, rosuvastatin ≧20 mg/day and simvastatin ≧80 mg/day; (2) moderate-intensity statins: 10 mg/day ≦ atorvastatin \<40 mg/day, 5 mg/day ≦ rosuvastatin \<20 mg/day, 20 mg/day ≦ simvastatin \<80 mg/day, pravastatin ≧40 mg/day, lovastatin ≧40 mg/day and fluvastatin ≧80 mg/day; and (3) low-intensity statins: atorvastatin \<10 mg/day, rosuvastatin \<5 mg/day, simvastatin \<20 mg/day, pravastatin \<40 mg/day, lovastatin \<40 mg/day and fluvastatin \<80 mg/day.

Combinations, statin + other lipid-modifying agents.

ACC/AHA, American College of Cardiology/American Heart Association; LDL-C, low-density lipoprotein cholesterol; NA, not applicable.

During the study period, almost all patients were prescribed with a single statin when they first started (98.6% in 2002 and 94.0% in 2011). Only 1.4% of patients were prescribed with combination therapy in 2002, with fibrates accounting for 83.3% of the combination therapies. Use of combination therapy increased to 6.0% in 2011, with ezetimibe accounting for 66.2% of combined lipid-lowering drugs.

In 2002, prescription rates of low-intensity and moderate-intensity statins were similar (51.0% and 49.0%). However, prescription rates of moderate-intensity statins gradually increased to 71.0% in 2011, while prescription rates of low-intensity statins gradually decreased to 27.3% in 2011. In comparison, use of high-intensity statins remained low (under 2.1%) during the study period ([figure 2](#F2){ref-type="fig"}).

![Prescribing rates of statins by intensity. All values were calculated in patient number. Yearly prescription rate = number of patients prescribed with the specific statin agent / total number of new statin users in the year. Statins were grouped into three levels of intensity according to their ability to lower LDL-C based on the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol[@R7] and Rosenson *et al* [@R28]: (1) high-intensity statins: atorvastatin ≧40 mg/day, rosuvastatin ≧20 mg/day and simvastatin ≧80 mg/day; (2) moderate-intensity statins: 10 mg/day ≦ atorvastatin \<40 mg/day, 5 mg/day ≦ rosuvastatin \<20 mg/day, 20 mg/day ≦ simvastatin \<80 mg/day, pravastatin ≧ 40 mg/day, lovastatin ≧40 mg/day and fluvastatin ≧80 mg/day; and (3) low-intensity statins: atorvastatin \<10 mg/day, rosuvastatin \<5 mg/day, simvastatin \<20 mg/day, pravastatin \<40 mg/day, lovastatin \<40 mg/day and fluvastatin \<80 mg/day. ACC/AHA, American College of Cardiology/American Heart Association; LDL-C, low-density lipoprotein cholesterol.](bmjopen-2016-014150f02){#F2}

[Table 3](#T3){ref-type="table"} and [figure 3](#F3){ref-type="fig"} show the prescription rates of statins among new statin users with/without history of specific diseases. Compared with those without CVD, higher percentages of people with history of coronary events or cerebrovascular events were prescribed atorvastatin (51.4% vs 35.6% and 42.7% vs 35.4%, respectively, in 2011) or rosuvastatin (32.5% vs 19.3% and 27.5% vs 19.1%, respectively, in 2011). In patients with myopathy or liver injury history, prescription rates of different statins did not vary greatly through the study period compared with those without history of the diseases. Similarly, prescription rates of different statins did not vary greatly between people with and without diabetes.

![Prescribing rates of statins among new statin users with/without history of specific diseases.](bmjopen-2016-014150f03){#F3}

###### 

Prescription rates of statins among new statin users with/without disease history

  Year                                                        **2002**            **2003**              **2004**              **2005**              **2006**              **2007**              **2008**              **2009**              **2010**              **2011**    
  -------------------------------------------- -------------- ----------- ------- ----------- --------- ----------- --------- ----------- --------- ----------- --------- ----------- --------- ----------- --------- ----------- --------- ----------- --------- ----------- -------
  Yearly number of new statin users            5956                       9056                10 924                10 253                12 178                13 535                15 233                16 499                17 509                17 755                
  **With coronary events history**             NA             NA          NA      NA          **201**   **1.8%**    **179**   **1.7%**    **232**   **1.9%**    **219**   **1.6%**    **254**   **1.7%**    **301**   **1.8%**    **309**   **1.8%**    **286**   **1.6%**    
                                               Atorvastatin   NA          NA      NA          NA        104         51.7%     93          52.0%     93          40.1%     94          42.9%     125         49.2%     152         50.5%     159         51.5%     147         51.4%
                                               Fluvastatin    NA          NA      NA          NA        32          15.9%     29          16.2%     27          11.6%     24          11.0%     21          8.3%      21          7.0%      14          4.5%      7           2.5%
                                               Lovastatin     NA          NA      NA          NA        12          6.0%      10          5.6%      11          4.7%      7           3.2%      4           1.6%      8           2.7%      4           1.3%      4           1.4%
                                               Pravastatin    NA          NA      NA          NA        18          9.0%      10          5.6%      21          9.1%      13          5.9%      10          3.9%      15          5.0%      7           2.3%      13          4.6%
                                               Rosuvastatin   NA          NA      NA          NA        NA          NA        6           3.4%      59          25.4%     64          29.2%     76          29.9%     85          28.2%     103         33.3%     93          32.5%
                                               Simvastatin    NA          NA      NA          NA        35          17.4%     31          17.3%     21          9.1%      17          7.8%      18          7.1%      20          6.6%      22          7.1%      22          7.7%
  **Without coronary events history**          NA             NA          NA      NA          10 723    **98.2%**   10 074    **98.3%**   11 946    **98.1%**   13 316    **98.4%**   14 979    **98.3%**   16 198    **98.2%**   17 200    **98.2%**   17 469    **98.4%**   
                                               Atorvastatin   NA          NA      NA          NA        3822        35.6%     3517        34.9%     3790        31.7%     4007        30.1%     4197        28.0%     4760        29.4%     5682        33.0%     6210        35.6%
                                               Fluvastatin    NA          NA      NA          NA        1031        9.6%      1130        11.2%     1082        9.1%      1190        8.9%      1263        8.4%      1172        7.2%      1172        6.8%      1056        6.0%
                                               Lovastatin     NA          NA      NA          NA        3583        33.4%     3102        30.8%     2940        24.6%     2291        17.2%     1961        13.1%     1716        10.6%     1238        7.2%      1021        5.8%
                                               Pravastatin    NA          NA      NA          NA        795         7.4%      677         6.7%      745         6.2%      763         5.7%      995         6.6%      1107        6.8%      1431        8.3%      1663        9.5%
                                               Rosuvastatin   NA          NA      NA          NA        NA          NA        342         3.4%      1631        13.7%     2153        16.2%     2663        17.8%     2997        18.5%     3293        19.2%     3371        19.3%
                                               Simvastatin    NA          NA      NA          NA        1494        13.9%     1308        13.0%     1765        14.8%     2924        22.0%     3902        26.1%     4458        27.5%     4390        25.5%     4168        23.9%
  **With cerebrovascular events history**      NA             NA          NA      NA          NA        NA          NA        NA          **661**   **5.4%**    **735**   **5.4%**    **820**   **5.4%**    **821**   **5.0%**    **893**   **5.1%**    **878**   **5.0%**    
                                               Atorvastatin   NA          NA      NA          NA        NA          NA        NA          NA        315         47.7%     325         44.2%     328         40.0%     321         39.1%     389         43.6%     375         42.7%
                                               Fluvastatin    NA          NA      NA          NA        NA          NA        NA          NA        68          10.3%     71          9.7%      77          9.4%      68          8.3%      78          8.7%      63          7.2%
                                               Lovastatin     NA          NA      NA          NA        NA          NA        NA          NA        62          9.4%      52          7.1%      61          7.4%      48          5.9%      43          4.8%      26          3.0%
                                               Pravastatin    NA          NA      NA          NA        NA          NA        NA          NA        48          7.3%      41          5.6%      53          6.5%      39          4.8%      40          4.5%      59          6.7%
                                               Rosuvastatin   NA          NA      NA          NA        NA          NA        NA          NA        99          15.0%     149         20.3%     173         21.1%     201         24.5%     223         25.0%     241         27.5%
                                               Simvastatin    NA          NA      NA          NA        NA          NA        NA          NA        69          10.4%     97          13.2%     128         15.6%     146         17.8%     120         13.4%     115         13.1%
  **Without cerebrovascular events history**   NA             NA          NA      NA          NA        NA          NA        NA          11 517    **94.6%**   12 800    **94.6%**   14 413    **94.6%**   15 678    **95.0%**   16 616    **94.9%**   16 877    **95.1%**   
                                               Atorvastatin   NA          NA      NA          NA        NA          NA        NA          NA        3568        31.0%     3776        29.5%     3994        27.7%     4591        29.3%     5452        32.8%     5982        35.4%
                                               Fluvastatin    NA          NA      NA          NA        NA          NA        NA          NA        1041        9.0%      1143        8.9%      1207        8.4%      1125        7.2%      1108        6.7%      1000        5.9%
                                               Lovastatin     NA          NA      NA          NA        NA          NA        NA          NA        2889        25.1%     2246        17.6%     1904        13.2%     1676        10.7%     1199        7.2%      999         5.9%
                                               Pravastatin    NA          NA      NA          NA        NA          NA        NA          NA        718         6.2%      735         5.7%      952         6.6%      1083        6.9%      1398        8.4%      1617        9.6%
                                               Rosuvastatin   NA          NA      NA          NA        NA          NA        NA          NA        1591        13.8%     2067        16.2%     2566        17.8%     2881        18.4%     3173        19.1%     3223        19.1%
                                               Simvastatin    NA          NA      NA          NA        NA          NA        NA          NA        1717        14.9%     2843        22.2%     3792        26.3%     4332        27.6%     4292        25.8%     4075        24.2%
  **With diabetes history**                    1947           **32.7%**   2884    **31.8%**   3212      **29.4%**   3272      **31.9%**   3888      **31.9%**   4362      **32.2%**   4785      **31.4%**   5366      **32.5%**   5737      **32.8%**   5540      **31.2%**   
                                               Atorvastatin   705         36.2%   1177        40.8%     1287        40.1%     1207        36.9%     1256        32.3%     1360        31.2%     1302        27.2%     1602        29.9%     1870        32.6%     1987        35.9%
                                               Fluvastatin    227         11.7%   273         9.5%      293         9.1%      398         12.2%     392         10.1%     366         8.4%      445         9.3%      422         7.9%      437         7.6%      343         6.2%
                                               Lovastatin     428         22.0%   747         25.9%     919         28.6%     857         26.2%     842         21.7%     702         16.1%     572         12.0%     541         10.1%     389         6.8%      325         5.9%
                                               Pravastatin    237         12.2%   287         10.0%     232         7.2%      233         7.1%      276         7.1%      259         5.9%      332         6.9%      365         6.8%      496         8.7%      531         9.6%
                                               Rosuvastatin   NA          NA      NA          NA        NA          NA        140         4.3%      595         15.3%     754         17.3%     941         19.7%     1024        19.1%     1126        19.6%     1042        18.8%
                                               Simvastatin    350         18.0%   400         13.9%     481         15.0%     437         13.4%     528         13.6%     923         21.2%     1194        25.0%     1414        26.4%     1421        24.8%     1317        23.8%
  **Without diabetes history**                 4009           **67.3%**   6172    **68.2%**   7712      **70.6%**   6981      **68.1%**   8290      **68.1%**   9173      **67.8%**   10 448    **68.6%**   11 133    **67.5%**   11 772    **67.2%**   12 215    **68.8%**   
                                               Atorvastatin   1309        32.7%   2143        34.7%     2639        34.2%     2403        34.4%     2627        31.7%     2741        29.9%     3020        28.9%     3310        29.7%     3971        33.7%     4370        35.8%
                                               Fluvastatin    483         12.1%   582         9.4%      770         10.0%     761         10.9%     717         8.7%      848         9.2%      839         8.0%      771         6.9%      749         6.4%      720         5.9%
                                               Lovastatin     1045        26.1%   2082        33.7%     2676        34.7%     2255        32.3%     2109        25.4%     1596        17.4%     1393        13.3%     1183        10.6%     853         7.3%      700         5.7%
                                               Pravastatin    417         10.4%   504         8.2%      581         7.5%      454         6.5%      490         5.9%      517         5.6%      673         6.4%      757         6.8%      942         8.0%      1145        9.4%
                                               Rosuvastatin   NA          NA      NA          NA        NA          NA        208         3.0%      1095        13.2%     1462        15.9%     1798        17.2%     2058        18.5%     2270        19.3%     2422        19.8%
                                               Simvastatin    756         18.9%   862         14.0%     1048        13.6%     902         12.9%     1258        15.2%     2018        22.0%     2726        26.1%     3064        27.5%     2991        25.4%     2873        23.5%
  **With myopathy history**                    NA             NA          NA      NA          2924      **26.8%**   2806      **27.4%**   3342      **27.4%**   3816      **28.2%**   4202      **27.6%**   4502      **27.3%**   4068      **23.2%**   5061      **28.5%**   
                                               Atorvastatin   NA          NA      NA          NA        1036        35.4%     949         33.8%     1016        30.4%     1135        29.7%     1102        26.2%     1308        29.1%     1616        39.7%     1769        35.0%
                                               Fluvastatin    NA          NA      NA          NA        289         9.9%      314         11.2%     299         9.0%      332         8.7%      355         8.5%      319         7.1%      335         8.2%      279         5.5%
                                               Lovastatin     NA          NA      NA          NA        979         33.5%     895         31.9%     880         26.3%     671         17.6%     581         13.8%     486         10.8%     364         9.0%      291         5.8%
                                               Pravastatin    NA          NA      NA          NA        214         7.3%      190         6.8%      200         6.0%      199         5.2%      281         6.7%      302         6.7%      448         11.0%     470         9.3%
                                               Rosuvastatin   NA          NA      NA          NA        NA          NA        110         3.9%      479         14.3%     595         15.6%     713         17.0%     814         18.1%     923         22.7%     924         18.3%
                                               Simvastatin    NA          NA      NA          NA        407         13.9%     348         12.4%     472         14.1%     888         23.3%     1170        27.8%     1277        28.4%     1283        31.5%     1331        26.3%
  **Without myopathy history**                 NA             NA          NA      NA          8000      **73.2%**   7447      **72.6%**   8836      **72.6%**   9719      **71.8%**   11 031    **72.4%**   11 997    **72.7%**   12 541    **71.6%**   12 694    **71.5%**   
                                               Atorvastatin   NA          NA      NA          NA        2890        36.1%     2661        35.7%     2867        32.5%     2966        30.5%     3220        29.2%     3604        30.0%     4225        33.7%     4588        36.1%
                                               Fluvastatin    NA          NA      NA          NA        774         9.7%      845         11.4%     810         9.2%      882         9.1%      929         8.4%      874         7.3%      851         6.8%      784         6.2%
                                               Lovastatin     NA          NA      NA          NA        2616        32.7%     2217        29.8%     2071        23.4%     1627        16.7%     1384        12.6%     1238        10.3%     878         7.0%      734         5.8%
                                               Pravastatin    NA          NA      NA          NA        599         7.5%      497         6.7%      566         6.4%      577         5.9%      724         6.6%      820         6.8%      990         7.9%      1206        9.5%
                                               Rosuvastatin   NA          NA      NA          NA        NA          NA        238         3.2%      1211        13.7%     1622        16.7%     2026        18.4%     2268        18.9%     2473        19.7%     2540        20.0%
                                               Simvastatin    NA          NA      NA          NA        1122        14.0%     991         13.3%     1314        14.9%     2053        21.1%     2750        24.9%     3201        26.7%     3129        25.0%     2859        22.5%
  **With liver injury history**                NA             NA          NA      NA          **856**   **7.8%**    **798**   **7.8%**    **907**   **7.4%**    1040      **7.7%**    1075      **7.1%**    1187      **7.2%**    1375      **7.9%**    1403      **7.9%**    
                                               Atorvastatin   NA          NA      NA          NA        369         43.1%     304         38.1%     294         32.4%     301         28.9%     324         30.1%     367         30.9%     429         31.2%     519         37.0%
                                               Fluvastatin    NA          NA      NA          NA        69          8.1%      86          10.8%     90          9.9%      91          8.8%      79          7.4%      79          6.7%      94          6.8%      84          6.0%
                                               Lovastatin     NA          NA      NA          NA        255         29.8%     219         27.4%     211         23.3%     183         17.6%     123         11.4%     88          7.4%      79          5.8%      75          5.4%
                                               Pravastatin    NA          NA      NA          NA        51          6.0%      45          5.6%      65          7.2%      65          6.3%      68          6.3%      86          7.3%      134         9.8%      147         10.5%
                                               Rosuvastatin   NA          NA      NA          NA        NA          NA        31          3.9%      121         13.3%     169         16.3%     198         18.4%     221         18.6%     258         18.8%     246         17.5%
                                               Simvastatin    NA          NA      NA          NA        112         13.1%     113         14.2%     127         14.0%     232         22.3%     284         26.4%     346         29.2%     381         27.7%     332         23.7%
  **Without liver injury history**             NA             NA          NA      NA          10 068    **92.2%**   9455      **92.2%**   11 271    **92.6%**   12 495    **92.3%**   14 158    **92.9%**   15 312    **92.8%**   16 134    **92.1%**   16 352    **92.1%**   
                                               Atorvastatin   NA          NA      NA          NA        3557        35.3%     3306        35.0%     3589        31.8%     3800        30.4%     3998        28.2%     4545        29.7%     5412        33.5%     5838        35.7%
                                               Fluvastatin    NA          NA      NA          NA        994         9.9%      1073        11.4%     1019        9.0%      1123        9.0%      1205        8.5%      1114        7.3%      1092        6.8%      979         6.0%
                                               Lovastatin     NA          NA      NA          NA        3340        33.2%     2893        30.6%     2740        24.3%     2115        16.9%     1842        13.0%     1636        10.7%     1163        7.2%      950         5.8%
                                               Pravastatin    NA          NA      NA          NA        762         7.6%      642         6.8%      701         6.2%      711         5.7%      937         6.6%      1036        6.8%      1304        8.1%      1529        9.4%
                                               Rosuvastatin   NA          NA      NA          NA        NA          NA        317         3.4%      1569        13.9%     2048        16.4%     2541        18.0%     2861        18.7%     3138        19.5%     3218        19.7%
                                               Simvastatin    NA          NA      NA          NA        1417        14.1%     1226        13.0%     1659        14.7%     2709        21.7%     3636        25.7%     4132        27.0%     4031        25.0%     3858        23.6%

Individuals were defined as having a history of the following diseases if they have a diagnosis within certain years prior to the given year: coronary event (3 years), cerebrovascular event (5 years), diabetes (1 year), myopathy (3 years) and liver injury (3 years).

NA, not available.

[Table 4](#T4){ref-type="table"} indicates the findings of the associations between certain disease history and prescription of high- or moderate-intensity statins. Patients with CVD history were more likely to be prescribed moderate-intensity or high-intensity statins (OR ranged from 1.52 to 2.83 during the study period, p\<0.05). Similar results were found in patients with cerebrovascular events history compared with those without (OR ranged from 1.17 to 1.88 during 2006--2011, p\<0.05). However, patients with diabetes history were less likely to be prescribed moderate-intensity or high-intensity statins compared with patients without diabetes history (OR ranged from 0.83 to 0.90 during 2007--2011, p\<0.05). No substantial differences in prescribing patterns of statins were observed throughout the study period in groups with versus without history of myopathy or liver injury ([table 4](#T4){ref-type="table"}).

###### 

Associations between disease history and prescription of moderate-intensity or high-intensity statins

  Year                                2004              2005             2006             2007             2008             2009             2010             2011
  ----------------------------------- ----------------- ---------------- ---------------- ---------------- ---------------- ---------------- ---------------- ----------------
  History of coronary events          2.04^\*^          2.55^\*^         2.83^\*^         1.69^\*^         2.39^\*^         1.80\*           2.06\*           1.52\*
                                      (1.51 to  2.76)   (1.80 to 3.59)   (2.01 to 3.99)   (1.22 to 2.35)   (1.66 to 3.44)   (1.34 to 2.42)   (1.52 to 2.80)   (1.13 to 2.03)
  History of cerebrovascular events   --                --               1.88^\*^         1.61^\*^         1.17^\*^         1.40\*           1.66\*           1.61\*
                                      --                --               (1.56 to 2.25)   (1.34 to 1.93)   (0.99 to 1.38)   (1.18 to 1.65)   (1.40 to 1.96)   (1.36 to 1.91)
  History of diabetes                 1.17^\*^          1.08^\*^         1.01             0.88^\*^         0.90^\*^         0.83\*           0.85\*           0.83\*
                                      (1.08 to 1.27)    (0.99 to 1.18)   (0.93 to 1.09)   (0.81 to 0.95)   (0.83 to 0.97)   (0.77 to 0.89)   (0.79 to 0.91)   (0.77 to 0.89)
  History of myopathy                 0.97              0.95             0.93             0.99             0.97             1.00             0.94             0.96
                                      (0.89 to 1.05)    (0.87 to 1.04)   (0.86 to 1.01)   (0.91 to 1.07)   (0.90 to 1.05)   (0.73 to 1.08)   (0.87 to 1.01)   (0.89 to 1.03)
  History of liver injury             1.29^\*^          1.19             0.96             1.04             1.10             1.15\*           0.95             1.04
                                      (1.12 to 1.49)    (1.02 to 1.37)   (0.84 to 1.11)   (0.91 to 1.20)   (0.95 to 1.27)   (1.00 to 1.31)   (0.84 to 1.07)   (0.92 to 1.17

\*Indicates significant difference in prescription rate between patient with certain medical history and those without; p value \<0.05.

†OR was calculated as the odds of being prescribed high-intensity or moderate-intensity statins for those with certain disease history compared with those without.

Statins were grouped into three levels of intensity according to its ability of lowering LDL-C based on 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol[@R7] and Rosenson *et al* [@R28]: (1) high-intensity statins: atorvastatin 40 mg/day, rosuvastatin  20 mg/day and simvastatin 80 mg/day; (2) moderate-intensity statins: 10  mg/day atorvastatin \< 40?mg/day, 5 mg/day rosuvastatin \< 20 mg/day, 20 mg/day simvastatin \< 80 mg/day, pravastatin 40 mg/day, lovastatin 40 mg/day and fluvastatin 80 mg/day; and (3) low-intensity statins: atorvastatin \<10 mg/day, rosuvastatin \<5 mg/day, simvastatin \<20 mg/day, pravastatin \<40 mg/day, lovastatin \<40 mg/day and fluvastatin \<80 mg/ day. Individuals were defined as having a history of the following diseases if they have a diagnosis within certain years prior to the given year: coronary event (3 years), cerebrovascular event (5 years), diabetes (1 year), myopathy (3 years) and liver injury (3 years).

ACC/AHA, American College of Cardiology/American Heart Association; LDL-C, low-density lipoprotein cholesterol.

Discussion {#s4}
==========

This longitudinal study of a national cohort found that more than half statin users were initiated on a single statin, with atorvastatin being the most commonly prescribed statin over the last decade in Taiwan. Use of moderate-intensity statins increased by 22.0% between 2002 and 2011, while use of high-intensity statins remained low. Lastly, patients with history of coronary events or cerebrovascular events were more likely to be prescribed higher intensity statins compared with those without. Prescribing of higher intensity statins was not greater among people with diabetes compared with those without during 2007--2011. This difference was also not seen in people with versus without history of myopathy or liver injury.

From 2002 to 2011, initiation of statins increased over time, similar to studies from other countries.[@R18] Initiation of statins in Taiwan has grown from 0.6% in 2002 to 1.8% in 2011. Our findings are similar to studies from other countries that found similar utilisation rates and increasing trend over time. For instance, a study used data of Italian local pharmacies and demonstrated incidence of statin exposure growing from 0.36% in 1994 to 0.74% in 2003.[@R42] Another study, which was also conducted in Italy, exhibited yearly incidence of statin use increasing from 13.3/1000 inhabitants in 2005 to 19.5/1000 inhabitants in 2010 among people aged 15 and over.[@R39] A study by Svensson *et al* aligned with the previous results showing annual rates of new statin use ranging from 14 to 20/1000 person-years.[@R40]

Our study found that atorvastatin had the highest prescription rate in Taiwan throughout the entire study. It was first introduced into Taiwan's market in 2000 and its market share surged to surpass other agents of the same drug class since the first study year.[@R21] In other countries, atorvastatin has also been one of the most commonly used statins.[@R39] The popularity of atorvastatin might be attributed to favourable research results suggesting its clinical benefits in preventing major coronary events[@R44] as well as marketing strategies of the pharmaceutical company.[@R45] When examining trends of different statins, it was noted that trends of atorvastatin and simvastatin exhibited opposite directions ([figure 1](#F1){ref-type="fig"}). Since both statins were moderate-to-high potency agents, their similar potency may be a reason for the substitution observed.[@R12] Another high-potency statin―rosuvastatin―manifested an increase in prescription rates since its market entry at 2005. The growth in use of atorvastatin, simvastatin (+/- ezetimibe) and rosuvastatin suggests treatment trending towards use of high-potency or moderate-to-high-intensity statin therapy, which is aligned with major clinical guidelines.[@R7]

The majority of statin regimen stayed within the moderate-intensity range rather than high-intensity therapy, which remained less than 5% during the study period. In a study from USA, relatively lower percentage (approximately 20% of total statin use) of high-intensity statin therapy was reported among adults ≧40 years old during 2002--2013.[@R47] In comparison, our study reveals substantially low use of high-intensity statin, suggesting that there is room for improving rational use of statins in Taiwan.

Few statin users initiated with combination therapy overall. Use of combined lipid-lowering agents shifted from fibrates (83.3% in 2002) to ezetimibe (66.2% in 2011). Ezetimibe entered Taiwan's market under the National Insurance coverage in 2006 as a combination drug with simvastatin (tradename Vytorin). High uptake of ezetimibe products might be associated with the evidence that ezetimibe plus simvastatin is more effective in lowering LDL-C than simvastatin alone.[@R48]

Our findings demonstrated an association between having a history of CVD and high-intensity or moderate-intensity statin use. Similarly other studies have reported that patients with CVD histories were prescribed statins with higher intensity or doses.[@R19] Use of statins among these individuals might have been appropriately influenced by clinical guidelines and related evidence suggesting more intensive statin therapy reduces cardiovascular events in patients with prior CVD.[@R22] While diabetes has been viewed as a coronary risk equivalent,[@R51] we did not find greater use of higher intensity statins among those with diabetes. A possible explanation might include the accumulating evidence suggesting the association between statin use and increasing risk of diabetes[@R52] and the deterioration of glucose control in patients receiving higher intensity statin regimens.[@R54] Appropriateness of statin use among diabetes needs further investigation. Interestingly, we did not find different patterns of statin use between those with and without history of myopathy or liver diseases. This finding suggests that these side effects might not be of a primary concern when prescribing statin therapy in Taiwan.

This study contributes to the literature by examining the prescribing patterns of statins during 2002--2011 in Taiwan, including statin choices among patients with certain medical histories. Despite these strengths, it does have limitations. First, our analysis was based on claims data, which do not contain patients' biochemical test data (such as level of LDL-C), so we could not assess prescription patterns by disease severity. Second, this study only examined statin use among new users; we did not assess switches between statins. Further research is needed to address these gaps. As new PCSK9 inhibitors become available on Taiwan's NHI, our findings provide baseline trends that can be used in a future study to examine how new PCSK9 inhibitors impact the market of cholesterol medications.

Conclusion {#s5}
==========

Our study with national cohorts of new statin users in each year during 2002--2011 in Taiwan found that the majority of new users initiated on statin monotherapy, and atorvastatin was the most commonly prescribed statin. While patients with history of CVD were more likely to be prescribed higher intensity statins compared with those without, which is consistent with clinical guidelines, such difference was not found comparing those with and without diabetes. Appropriateness of statin use among diabetes needs further investigation.
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